• Vaccine Name: Lassa fever virus recombinant vector vaccine V-LSG/N encoding the glycoprotein and the nucleoprotein
• Target Pathogen: Lassa Fever Virus
• Target Disease: Lassa fever
• Vaccine Ontology ID: VO_0004379
• Type: Recombinant vector vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Macaque
• LASVsSgp1 nucleoprotein gene engineering:
  • Type: Recombinant vector construction
  • Description: Vector NYBH strains of vaccinia virus expressed the nucleoprotein (Fisher-Hoch et al., 2000).
  • Detailed Gene Information: Click Here.
• LASVsSgp2 glycoprotein gene engineering:
  • Type: Recombinant vector construction
  • Description: Vector NYBH strains of vaccinia virus expressed the glycoprotein (Fisher-Hoch et al., 2000).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Monkey Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: The protection of our animals by Lassa virus glycoprotein expressed in vaccinia virus in the face of a low antibody response supports that antibody alone does not provide protection. Proper folding of LCMV glycoprotein is critical for induction of the humoral response and vaccinia virus-expressed glycoproteins are not posttranslationally processed or transported correctly to the membrane. Thus, the minimal measurable antibody response to glycoprotein after vaccination may be related to improperly folded glycoprotein (Fisher-Hoch et al., 2000).
• Efficacy: 9 of 10 monkeys that received the V-LSG/N vaccine survived challenge with Lassa virus (Fisher-Hoch et al., 2000).